The Strategic Role of Biomarkers in Drug Discovery and Clinical Trials Every decision in drug development carries weight. The ...

Purple Biotech Ltd. has announced promising new data regarding its therapy NT219, a dual inhibitor targeting IRS1/2 and STAT3, for the treatment of head and neck squamous cell carcinoma (HNSCC) and ...

We’re in the midst of a paradigm shift in biomarker science. Once considered exploratory, biomarker signatures have evolved into strategic assets - tools that actively de-risk decision-making across ...

78% reduction in risk of death and 81% reduction in risk of progression or death in defined pretreatment ranges of serum or tumor CEACAM1 subgroup 61% reduction is risk of death and 72% reduction in ...

The Phase 1b trial consisted of 24 patients with Parkinson’s disease, who received twice-weekly dosing of either HER-096 or placebo over a four-week period. The trial’s exploratory biomarker program ...

aiwell Inc., a biotech startup originating from Tokyo University of Science, has identified protein biomarkers associated with menopause. Using its proprietary AI‑driven proteomics platform aiwell IPA ...

BostonGene, developer of the leading AI foundation model for tumor and immune biology, today announced it has been named “Overall Immunology Company of the Year” in the fifth annual BioTech ...